Á lódáil...

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

Although most autoimmune diseases are considered to be CD4 T cell‐ or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off‐label in...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Clin Exp Immunol
Main Authors: Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., Amor, S.
Formáid: Artigo
Teanga:Inglês
Foilsithe: John Wiley and Sons Inc. 2020
Ábhair:
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7405500/
https://ncbi.nlm.nih.gov/pubmed/32671831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13495
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!